Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy

Introduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, altho...

Full description

Autores:
Barrón-Barrón, Feliciano
Sánchez, Roberto P.
Arroyo-Hernández, Marisol
Blanco, Carolina
Zatarain-Barrón, Zyanya Lucia
Catalán, Rodrigo
Ramos-Ramírez, Maritza
Cardona-Mendoza, Andrés Felipe
Flores-Estrada, Diana
Arrieta, Oscar
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/5058
Acceso en línea:
http://hdl.handle.net/20.500.12495/5058
https://doi.org/10.3389/fonc.2020.570233
Palabra clave:
Checkpoint immune therapy
Pneumonitis
Radiotherapy
NSCLC
Lung cancer
Immune related adverse effects
Rights
openAccess
License
Attribution 4.0 International
id UNBOSQUE2_2347cb0d2427f9628527651a7616b74f
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/5058
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
dc.title.translated.spa.fl_str_mv Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
title Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
spellingShingle Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
Checkpoint immune therapy
Pneumonitis
Radiotherapy
NSCLC
Lung cancer
Immune related adverse effects
title_short Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
title_full Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
title_fullStr Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
title_full_unstemmed Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
title_sort Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
dc.creator.fl_str_mv Barrón-Barrón, Feliciano
Sánchez, Roberto P.
Arroyo-Hernández, Marisol
Blanco, Carolina
Zatarain-Barrón, Zyanya Lucia
Catalán, Rodrigo
Ramos-Ramírez, Maritza
Cardona-Mendoza, Andrés Felipe
Flores-Estrada, Diana
Arrieta, Oscar
dc.contributor.author.none.fl_str_mv Barrón-Barrón, Feliciano
Sánchez, Roberto P.
Arroyo-Hernández, Marisol
Blanco, Carolina
Zatarain-Barrón, Zyanya Lucia
Catalán, Rodrigo
Ramos-Ramírez, Maritza
Cardona-Mendoza, Andrés Felipe
Flores-Estrada, Diana
Arrieta, Oscar
dc.contributor.orcid.none.fl_str_mv Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.subject.keywords.spa.fl_str_mv Checkpoint immune therapy
Pneumonitis
Radiotherapy
NSCLC
Lung cancer
Immune related adverse effects
topic Checkpoint immune therapy
Pneumonitis
Radiotherapy
NSCLC
Lung cancer
Immune related adverse effects
description Introduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, although a connection between antitumor immuneresponses and irAEs has been suggested. In this study, we evaluated the developmentof ICIP in non-small cell lung cancer patients with prior radiotherapy, treated withimmunotherapy in the second-line.Methods:In this retrospective trial, we included patients treated with second-lineimmunotherapy at the National Cancer Institute in Mexico City from February 2015 toFebruary 2018. Clinical, radiological and treatment variables were evaluated accordingto the presence of ICIP as defined by the Common Terminology Criteria for AdverseEvents (4.0) in patients with or without a previous (≥months) history of radiotherapy.Results:Among 101 NSCLC patients who received treatment with ICIs, 22 patients(21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy(OR 6.04, 95% CI 2.03−18.0,p<0.001). Median progression free survival and overallsurvival were similar in patients who developed ICIP compared with those who did not,however, patients who presented grade≥2 ICIP had an increased risk of mortality (HR2.54, 95% CI 1.20−5.34,p= 0.014).Conclusion:In this real-world cohort of NSCLC patients treated with ICI, the historyof prior radiotherapy was associated with increased risk for ICIP development. Unlikeother irAEs, grade≥2 ICIP is an independent prognostic factor for decreased survivalin NSCLC patients.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-11-12T21:40:33Z
dc.date.available.none.fl_str_mv 2020-11-12T21:40:33Z
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.none.fl_str_mv Artículo de revista
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
format http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 2234-943X
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/5058
dc.identifier.doi.none.fl_str_mv https://doi.org/10.3389/fonc.2020.570233
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 2234-943X
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/5058
https://doi.org/10.3389/fonc.2020.570233
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Frontiers in oncology, 2234-943X, Vol. 10, Nro. 29, 2020
dc.relation.uri.none.fl_str_mv https://www.frontiersin.org/articles/10.3389/fonc.2020.570233/full
dc.rights.*.fl_str_mv Attribution 4.0 International
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Acceso abierto
dc.rights.creativecommons.none.fl_str_mv 2020-09-29
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Acceso abierto
http://purl.org/coar/access_right/c_abf2
2020-09-29
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Frontiers Media S.A.
dc.publisher.journal.spa.fl_str_mv Frontiers in oncology
institution Universidad El Bosque
bitstream.url.fl_str_mv https://repositorio.unbosque.edu.co/bitstreams/667c4187-cc18-42fc-ab29-944a85beeeb8/download
https://repositorio.unbosque.edu.co/bitstreams/836b9f8b-db54-468c-bab4-8317494b416c/download
https://repositorio.unbosque.edu.co/bitstreams/aba3eac0-9d15-43d5-9757-c9a31677708d/download
https://repositorio.unbosque.edu.co/bitstreams/7a3536dd-6bb6-456f-8fae-73b6536ed1e0/download
https://repositorio.unbosque.edu.co/bitstreams/93162162-c675-4604-92ca-bcafd1116c97/download
bitstream.checksum.fl_str_mv 0175ea4a2d4caec4bbcc37e300941108
8a4605be74aa9ea9d79846c1fba20a33
e57d26e78f25f06bdb062d0ead01dcd7
afb55d74284c59ab1717c773e012d31e
a23c3b710ba1cdffe67db467837edd4a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1814100813053689856
spelling Barrón-Barrón, FelicianoSánchez, Roberto P.Arroyo-Hernández, MarisolBlanco, CarolinaZatarain-Barrón, Zyanya LuciaCatalán, RodrigoRamos-Ramírez, MaritzaCardona-Mendoza, Andrés FelipeFlores-Estrada, DianaArrieta, OscarCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]2020-11-12T21:40:33Z2020-11-12T21:40:33Z2234-943Xhttp://hdl.handle.net/20.500.12495/5058https://doi.org/10.3389/fonc.2020.570233instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengFrontiers Media S.A.Frontiers in oncologyFrontiers in oncology, 2234-943X, Vol. 10, Nro. 29, 2020https://www.frontiersin.org/articles/10.3389/fonc.2020.570233/fullAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2020-09-29Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapyRisk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapyArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Checkpoint immune therapyPneumonitisRadiotherapyNSCLCLung cancerImmune related adverse effectsIntroduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, although a connection between antitumor immuneresponses and irAEs has been suggested. In this study, we evaluated the developmentof ICIP in non-small cell lung cancer patients with prior radiotherapy, treated withimmunotherapy in the second-line.Methods:In this retrospective trial, we included patients treated with second-lineimmunotherapy at the National Cancer Institute in Mexico City from February 2015 toFebruary 2018. Clinical, radiological and treatment variables were evaluated accordingto the presence of ICIP as defined by the Common Terminology Criteria for AdverseEvents (4.0) in patients with or without a previous (≥months) history of radiotherapy.Results:Among 101 NSCLC patients who received treatment with ICIs, 22 patients(21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy(OR 6.04, 95% CI 2.03−18.0,p<0.001). Median progression free survival and overallsurvival were similar in patients who developed ICIP compared with those who did not,however, patients who presented grade≥2 ICIP had an increased risk of mortality (HR2.54, 95% CI 1.20−5.34,p= 0.014).Conclusion:In this real-world cohort of NSCLC patients treated with ICI, the historyof prior radiotherapy was associated with increased risk for ICIP development. Unlikeother irAEs, grade≥2 ICIP is an independent prognostic factor for decreased survivalin NSCLC patients.CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908https://repositorio.unbosque.edu.co/bitstreams/667c4187-cc18-42fc-ab29-944a85beeeb8/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/836b9f8b-db54-468c-bab4-8317494b416c/download8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALFeliciano Barrón, Roberto Sánchez_2020.pdfFeliciano Barrón, Roberto Sánchez_2020.pdfapplication/pdf730560https://repositorio.unbosque.edu.co/bitstreams/aba3eac0-9d15-43d5-9757-c9a31677708d/downloade57d26e78f25f06bdb062d0ead01dcd7MD51THUMBNAILFeliciano Barrón, Roberto Sánchez_2020.pdf.jpgFeliciano Barrón, Roberto Sánchez_2020.pdf.jpgIM Thumbnailimage/jpeg12922https://repositorio.unbosque.edu.co/bitstreams/7a3536dd-6bb6-456f-8fae-73b6536ed1e0/downloadafb55d74284c59ab1717c773e012d31eMD54TEXTFeliciano Barrón, Roberto Sánchez_2020.pdf.txtFeliciano Barrón, Roberto Sánchez_2020.pdf.txtExtracted texttext/plain42471https://repositorio.unbosque.edu.co/bitstreams/93162162-c675-4604-92ca-bcafd1116c97/downloada23c3b710ba1cdffe67db467837edd4aMD5520.500.12495/5058oai:repositorio.unbosque.edu.co:20.500.12495/50582024-02-07 08:25:45.277http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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